Optimising effectiveness in patients of existing prescription drugs for major diseases (except cancer) with the use of biomarkers
Programme Category
Programme Name
Programme Description
Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.
Identifier Code
Call
Summary
Proposals under this topic should aim for delivering results that are directed, tailored and contributing to all of the following expected outcomes:
a) Diagnostics industries move towards market approval for companion diagnostics.
b) Regulatory authorities approve companion diagnostics and make recommendations for the prescription of existing drugs.
c) Health care providers use biomarkers with existing pharmaceuticals to treat more efficiently and cost-effectively patients, with less adverse effects.
Detailed Call Description
The applicants should perform the clinical validation of qualified biomarkers (not limited to molecular biomarkers) that will enable the identification of appropriate patients to ensure an effective and efficient use of existing pharmaceuticals in the treatment of major diseases and conditions. The relevant biomarkers should allow providing the right medicinal product, at the right dose and the right time, according to the concept of personalised medicine, taking into account, among others, differences of sex, age, ethnicity and gender identity.
This topic refers to medicines that are already on the market and not to the validation of biomarkers for the development of new medicinal products. It addresses broadly prescribed medicines for major diseases and conditions, including but not limited to cardiovascular diseases. A condition is that preliminary studies or publications have demonstrated that the pharmaceuticals considered are efficient in less than 50% of the population treated.
This topic excludes cancer and rare disease treatments. The applicants should consider existing guidelines, standards and regulations, as appropriate. Synergies with relevant European Research Infrastructures are encouraged.
Call Total Budget
Financing percentage by EU or other bodies / Level of Subsidy or Loan
100%
Contribution per project: €10,00 million
Thematic Categories
- Enlargement
- Health
- Research, Technological Development and Innovation
Eligibility for Participation
- Central Government
- Private Bodies
- Researchers/Research Centers/Institutions
- State-owned Enterprises
Call Opening Date
Call Closing Date
National Contact Point(s)
Research and Innovation Foundation
29a Andrea Michalakopoulou, 1075 Nicosia
P.O.Box 23422, 1683 Nicosia
Telephone: +357 22205000
Email Address: support@research.org.cy
Website: https://www.research.org.cy/en/
Mr Marinos Fotiadis
Contact Phone: 22 205 048
E-mail: mphotiades@research.org.cy
Website: https://www.research.org.cy/
Dr Ioannis Theodorou
Contact Phone: 22 205 038
E-mail: itheodorou@research.org.cy
Website: https://www.research.org.cy/
(Publish Date: 23/11/2021-for internal use only)
EU Contact Point
European Commission, Directorate-General for Research and Innovation
https://ec.europa.eu/info/departments/research-and-innovation_en#contact